{
    "clinical_study": {
        "@rank": "51962", 
        "arm_group": {
            "arm_group_label": "MGA271", 
            "arm_group_type": "Experimental", 
            "description": "MGA271 (administered in main study CP-MGA271-01)"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to gain a better understanding about how the study drug MGA271\n      works. No test drug will be given in this study. Patients with easily accessible tumors at\n      the screening visit for participation in Study CP-MGA271-01 will be asked to participate in\n      this substudy. Patients will undergo two excisional biopsies, punch biopsies, or core needle\n      biopsies."
        }, 
        "brief_title": "Tissue Procurement Substudy for Participants in Study CP-MGA271-01", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Melanoma", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "detailed_description": {
            "textblock": "Patients with easily accessible tumors (generally, metastatic deposits involving skin,\n      subcutaneous tissues, or peripheral lymph node whose excision would not require general\n      anaesthesia or the invasion of a body cavity) at the screening visit for participation in\n      Study CP-MGA271-01 (the main study) will be asked to participate in this substudy. After\n      providing appropriate informed consent, patients will undergo excisional biopsy, punch\n      biopsy, or core needle biopsy of the accessible tumor prior to receiving study drug in the\n      main study and then again after the first cycle of study drug is completed.\n\n      Some of the biopsy tissue will be sent to a central laboratory for research purposes. The\n      central lab will analyze the tissue to see what effects that the study drug might have on\n      tumors."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Qualified, by meeting all inclusion and exclusion criteria, for participation in\n             Study CP-MGA271-01.\n\n          -  Must have provided informed consent to participate in Study CP-MGA271-01.\n\n          -  Must have accessible tumors (generally speaking, metastatic deposits involving skin,\n             subcutaneous tissue, or peripheral lymph node whose excision, punch biopsy, or core\n             needle biopsy would not require general anaesthesia or the invasion of a body\n             cavity).\n\n          -  Willing to undergo two minor surgical procedures with no expectation of personal\n             benefit\n\n          -  Have provided Informed Consent for this substudy as indicated by a signature on an\n             approved consent document obtained from the patient or his/her legally authorized\n             representative\n\n        Exclusion Criteria:\n\n          -  Any medical condition that would contraindicate the use of local or locoregional\n             anaesthesia, or conscious sedation for the intended minor surgical procedure.\n\n          -  Any medical condition (eg. skin disease or bleeding diathesis) that would hinder\n             wound healing following a minor surgical procedure.\n\n          -  Dementia or altered mental status that would preclude understanding and rendering of\n             informed consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "15", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01918930", 
            "org_study_id": "CP-MGA271-01a"
        }, 
        "intervention": {
            "arm_group_label": "MGA271", 
            "description": "MGA271 anti-B7-H3 monoclonal antibody", 
            "intervention_name": "MGA271", 
            "intervention_type": "Biological"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Melanoma", 
            "Accessible tumors", 
            "B7-H3 positive tumors"
        ], 
        "lastchanged_date": "August 6, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Greg Cote, MD", 
                    "phone": "617-724-4800"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Massachusetts General Hospital Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Greg Cote, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "maryann.redlinger@uphs.upenn.edu", 
                    "last_name": "Maryann Redlinger, RN", 
                    "phone": "215-662-7452"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19104"
                    }, 
                    "name": "Hospital of the University of Pennsylvania/Abramson Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Roger Cohen, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Nurse Referral Line", 
                    "phone": "615-339-4214"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Sarah Cannon Research Institute"
                }, 
                "investigator": {
                    "last_name": "Howard Burris, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Tissue Procurement and Examination Substudy of Study CP-MGA271-01 (NCT01391143)", 
        "overall_contact": {
            "email": "baughmanj@macrogenics.com", 
            "last_name": "Jan Baughman, MPH", 
            "phone": "650 624-2676"
        }, 
        "overall_official": {
            "affiliation": "MacroGenics", 
            "last_name": "Stanford J. Stewart, M.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Exploratory analyses from immunohistochemistry (IHC) and flow cytometry testing to determine the effect of MGA271 on tumor cells.", 
            "measure": "Mechanism of Action", 
            "safety_issue": "No", 
            "time_frame": "up to 50 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01918930"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "MacroGenics", 
        "sponsors": {
            "collaborator": {
                "agency": "Massachusetts General Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "MacroGenics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}